Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542043 | 0.85 | POLB (0.59) | ALDH1A1KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL7542036 | 0.85 | POLB (0.59) | ALDH1A1KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL7546114 | 0.83 | HRH3 (0.41) | ALDH1A1KDM4EKMT2AL3MBTL1HPGD | |
| SCHEMBL7546120 | 0.83 | HRH3 (0.41) | ALDH1A1KDM4EKMT2AL3MBTL1HPGD | |
| SCHEMBL7545912 | 0.81 | POLB (0.55) | ALDH1A1KDM4EKMT2AL3MBTL1HPGD | |
| SCHEMBL7546055 | 0.81 | POLB (0.55) | ALDH1A1KDM4EKMT2AL3MBTL1HPGD | |
| SCHEMBL7545915 | 0.81 | POLB (0.55) | ALDH1A1KDM4EKMT2AL3MBTL1HPGD | |
| SCHEMBL14259818 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL19143407 | 0.79 | HPGD (0.47) | ALDH1A1RAB9AKMT2AMEN1HPGD | |
| SCHEMBL23680948 | 0.79 | HPGD (0.47) | ALDH1A1RAB9AKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | ALDH1A1 3894/4885KDM4E 3023/4885NPC1 3131/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | ALDH1A1 3894/4885KDM4E 3023/4885NPC1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.